New drug combo aims to keep advanced lung cancer at bay
NCT ID NCT06606847
Summary
This study is testing whether adding a second drug (oleclumab) to an existing immunotherapy (durvalumab) can better control advanced lung cancer that cannot be surgically removed. It involves 30 adults in Russia whose cancer has not worsened after completing standard chemoradiation treatment. Participants will receive both drugs by IV infusion for up to one year to see if this combination delays cancer progression more effectively.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Kazan', 420029, Russia
-
Research Site
Moscow, 111123, Russia
-
Research Site
Moscow, 115478, Russia
-
Research Site
Moscow, 143423, Russia
-
Research Site
Nizhny Novgorod, 603126, Russia
-
Research Site
Novosibirsk, 630108, Russia
-
Research Site
Obninsk, 249031, Russia
-
Research Site
Saint Petersburg, 197022, Russia
-
Research Site
Saint Petersburg, 197758, Russia
-
Research Site
Ufa, 450054, Russia
-
Research Site
Yekaterinburg, 620905, Russia
Conditions
Explore the condition pages connected to this study.